Home
About
Capabilities
R&D
Investors
News
Careers
中文
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
Sep 05, 2025
Mabwell Secures Pakistan's First Denosumab Injection Approval
➞
Sep 02, 2025
First-in-Human Study Results of Mabwell's Novel Anti-ST2 Monoclonal Antibody 9MW1911 Selected for ERS 2025 Presentation
➞
Sep 01, 2025
Mabwell Announces NMPA Acceptance of IND Application for Novel Anti-IL-11 mAb 9MW3811 in Pathological Scarring
➞
Aug 19, 2025
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA
➞
Aug 12, 2025
Mabwell Announces First Patient Dosed in the US Clinical Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs
➞
Jul 31, 2025
Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA
➞
Jul 14, 2025
Mabwell Enters into License and Commercialization Agreement with UNILAB to Launch Denosumab Biosimilars in the Philippines
➞
Jul 01, 2025
Mabwell Passes Colombian GMP Inspection with “zero deficiencies” Result for Its Denosumab Injections
➞
Jun 27, 2025
Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection
➞
Jun 26, 2025
Mabwell Bioscience and Calico Life Sciences Announce Exclusive Licensing Agreement for Novel IL-11 Targeting Monoclonal Antibody
➞
1
2
3
Next